Polymer Nanosphere-Based Vaccination Strategies against Yersinia Pestis

Thursday, November 12, 2009: 8:30 AM
Hermitage C (Gaylord Opryland Hotel)

Bret D. Ulery, Chemical and Biological Engineering, Iowa State University, Ames, IA
Michael J. Wannemuehler, Veterinary Microbiology and Preventative Medicine, Iowa State University, Ames, IA
Jing Yu, Veterinary Microbiology and Preventative Medicine, Iowa State University, Ames, IA
F. Chris Minion, Veterinary Microbiology and Preventative Medicine, Iowa State University, Ames, IA
Devender Kumar, Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY
Dennis W. Metzger, Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY
Balaji Narasimhan, Chemical and Biological Engineering, Iowa State University, Ames, IA

Yersinia pestis, the causative agent of bubonic and pneumonic plague, is a Category A bioterrorism agent for which only moderately effective multi-dose whole-killed or live-attenuated vaccines currently exist. Subunit vaccines have been recently studied, but current strategies have shown only short-lived protection and require multiple injections. Our work is focused on the utilization of a fusion protein based (F1-V) vaccine, delivered with polyanhydride nanoparticle adjuvants as an inoculation strategy that will lead to a single-dose plague vaccine. For this study, random copolymers of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane and 1,6-bis(p-carboxyphenoxy)hexane were synthesized and fabricated into F1-V loaded nanoparticles by anti-solvent precipitation. Nanoparticles were delivered intranasally to C57BL/6 mice. Antigen-specific immune responses were assessed by antibody titers using an ELISA and lymphocyte proliferation was evaluated with 3H-thymidine and carboxyfluorescein succinimidyl ester incorporation. Cytokine secretion was measured using a LUMINEX bead assay. The results show that polyanhydride nanoparticle adjuvants can enhance and modulate the immune response in a way that can potentially improve the effectiveness of the F1-V vaccine and allow for single dose delivery. These studies provide evidence that polyanhydride nanoparticle vehicles hold great potential to be used in a wide variety of vaccination strategies.
Extended Abstract: File Not Uploaded